Assessment of B-type natriuretic peptide in patients with pneumonia

International Journal of Clinical Practice

Volumn 62, Issue 3, 2008, Pages 488-491

  Yetkin, O ^a   Hacievliyagil, S S ^a   Gunen, H ^a  

^a INONU UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HUMAN; LEUKOCYTE COUNT; MALE; PNEUMONIA; PRIORITY JOURNAL; STREPTOCOCCUS PNEUMONIAE;

ADULT; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; COMMUNITY-ACQUIRED INFECTIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PNEUMONIA;

EID: 38849192395     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2007.01305.x     Document Type: Article

References (25)

1. Sudoh T, Kangava T, Minamino N et al. A new natriuretic peptide in porcine brain. Nature 1988 332 : 78 81.
2. Saito Y, Nakao Y, Itoh H. Brain natriuretic peptide is a novel cardiac hormone. Biochem Biophys Res Commun 1989 158 : 360 8.
3. Tsutamoto T, Wada A, Maeda K et al. Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure: prognostic role of plasma brain natriuretic peptide concentration in patients with chronic symptomatic left ventricular dysfunction. Circulation 1997 96 : 509 16.
4. Sagnella GA. Measurement and significance of circulating natriuretic peptides in cardiovascular diseases. Clin Sci 1998 95 : 519 29.
5. Kawamura T, Wago M, Kawaguchi H, Tahara M, Yuge M. Plasma brain natriuretic peptide concentrations in patients with Kawasaki disease. Pediatr Int 2000 42 : 241 8.
6. Castillo JR, Zagler A, Carrillo-Jimenez R, Hennekens CH. Brain natriuretic peptide: a potential marker for mortality in septic shock. Int J Infect Dis 2004 8 : 271 4.
7. Arseven O, Ozlu T, Aydin G et al. Guidelines of Turkish thoracic society for the diagnosis and treatment of community-acquired pneumonia. Toraks Dergisi 2002 3 : S1 15.
8. Stein BC, Levin RI. Natriuretic peptides: physiology, therapeutic potential, and risk stratification in ischemic heart disease. Am Heart J 1998 135 : 914 23.
9. Wei T, Zeng C, Chen L et al. Systolic and diastolic heart failure are associated with different plasma levels of B-type natriuretic peptide. Int J Clin Pract 2005 59 : 891 4.
10. Kiely DG, Kennedy NS, Pirzada O et al. Elevated levels of natriuretic peptides in patients with pulmonary thromboembolism. Respir Med 2005 99 : 1286 91.
11. Marrie TJ. Therapeutic implications of macrolide resistance in pneumococcal community-acquired lower respiratory tract infections. Int J Clin Pract 2004 58 : 769 76.
12. Dudas V, Hopefl A, Jacobs R et al. Antimicrobial selection for hospitalized patients with presumed community-acquired pneumonia: a survey of nonteaching US community hospitals. Ann Pharmacother 2000 34 : 446 52.
13. Castell JV, Gomez-Lechon MJ, David M, Fabra R, Trullen R, Heinrich PC. Acute-phase response of human hepatocytes: regulation of acute-phase protein synthesis by interleukin-6. Hepatology 1990 12 : 1179 86.
14. Dinarello CA. Interleukin-1 and interleukin-1 antagonism. Blood 1991 77 : 1627 52.
15. Testa M, Yeh M, Lee P et al. Circulating levels of cytokines and their endogenous modulators in patients with mild to severe congestive heart failure due to coronary artery disease or hypertension. J Am Coll Cardiol 1996 28 : 964 71.
16. Shapiro SD. The macrophage in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999 160 : S29 S32.
17. Puren AJ, Feldman C, Savage N et al. Patterns of cytokine expression in community acquired pneumonia. Chest 1995 107 : 1342 49.
18. Bouwman JJ, Visseren FL, Bouter PK, Diepersloot RJ. Azithromycin inhibits interleukin-6 but not fibrinogen production in hepatocytes infected with cytomegalovirus and chlamydia pneumoniae. J Lab Clin Med 2004 144 : 18 26.
19. Antunes G, Evans SA, Lordan JL et al. Systemic cytokine levels in community-acquired pneumonia and their association with disease severity. Eur Respir J 2002 20 : 990 5.
20. He Q, LaPointe MC. Interleukin-1b regulation of the human brain natriuretic peptide promoter involves Ras-, Rac-, and p38 kinase-dependent pathways in cardia myocytes. Hypertension 1999 33 : 283 9.
21. Mueller C, Laule-Kilian K, Scholer A, Perruchoud AP. B-type natriuretic peptide for risk stratification in community-acquired pneumonia. J Intern Med 2005 258 : 391 3.
22. Ortega O, Gallar P, Munoz M et al. Association between C-reactive protein levels and N-terminal pro-B-type natriuretic peptide in pre-dialysis patients. Nephron Clin Pract 2004 97 : 125 30.
23. Sabatine MS, Morrow DA, de Lemos JA et al. Multimarker approach to risk stratification in non-ST elevation acute coronary syndromes: simultaneous assessment of troponin I, C-reactive protein, and B-type natriuretic peptide. Circulation 2002 105 : 1760 3.
24. Ando T, Ogawa K, Yamaki K et al. Plasma concentrations of atrial, brain, and C-type natriuretic peptides and endothelin-1 in patients with chronic respiratory diseases. Chest 1996 110 : 462 8.
25. Moine P, Vercken JB, Chevret S, Gajdos P. Severe community-acquired pneumococcal pneumonia. The French Study Group of Community-Acquired Pneumonia in ICU. Scand J Infect Dis 1995 27 : 201 6.